Acenocoumarol in Cerebrovascular Diseases
Patients with transient ischemic attack (TIA) or ischemic stroke are treated with oral anticoagulants to prevent recurrence of the primary disease. Acenocoumarol has been shown to be effective in prophylaxis against cerebrovascular events and its use is well-tolerated and not associated with a significant increase in hemorrhagic episodes.59,60
- Oral Anticoagulation in Cerebrovascular Disease
- Anticoagulant-Induced Intracerebral Bleeding
Oral anticoagulation in the secondary prevention of cerebrovascular disease. Long-term follow-up of 169 patients
Palomeras E et al., Rev Neurol. 1998 Nov;27(159):772-6.
To describe the complications and ischemic relapses in patients treated with oral anticoagulant for secondary prevention of cerebrovascular disease of cardiac embolic origin.
169 patients with embologenic cardiopathy who, following a cerebrovascular disease, were treated with oral anticoagulant and followed-up for at least 3 months.
Past clinical history and risk factors, occurrence of vascular relapses (VR), complications involving hemorrhage (CH), and data regarding course and follow-up.
- During an average follow-up of 50.3 months of a total of 707.9 patient/years:
- 20 VR (2.8% per year) were recorded; 15 of these were cerebrovascular and mainly mild.
- 59 CH in 41 patients (8.3% per year) of which 6 were considered to be major.
There is a low incidence of relapse and complications (usually mild) following oral anticoagulant for the secondary prevention of cerebrovascular disease of cardioembolic origin. Efficacy and security are maintained in the long-term.
Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart and progressing stroke
Bogousslavsky and Regli F, Acta Neurol Scand. 1985 Jun;71(6):464-71.
85 patients with transient ischemic attacks (TIAs), 65 patients with embolic brain ischemia of cardiac source and 50 patients with progressing stroke.
The patients received intravenous heparin within 96 hours of the event. Acenocoumarol was initiated in 108 patients after heparin therapy for 3-12 months.
Among the 108 patients who were placed on acenocoumarol therapy, only one (0.9%) suffered a hemorrhagic infarct from a probable recurrent embolization.